Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
Angion Biomedica Corp (NASDAQ:ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy. The trial began enrolling patients in December 2021. A reassessment was conducted following a potential safety signal of an unexpected and substantial…
Benzinga ·
Benzinga
